Natick-based Boston Scientific Corp. plans an immediate launch for its Taxus Liberte heart stent now that the system has been approved for sale in Canada.
Health Canada’s Therapeutic Products Directorate, the country’s pharmaceutical and medical device regulatory body, approved the drug-coated stent system for use. Stents prop open blood vessels in patients with coronary artery disease.
The Taxus Liberte system has also been approved for sale in Europe but has not been approved by the U.S. Food and Drug Administration and is not available in the U.S.
